235 related articles for article (PubMed ID: 37043580)
1. Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma.
Jiang Y; Yang J; Liang R; Zan X; Fan R; Shan B; Liu H; Li L; Wang Y; Wu M; Qi X; Chen H; Ren Q; Liu Z; Wang Y; Zhang J; Zhou P; Li Q; Tian M; Yang J; Wang C; Li X; Jiang S; Zhou L; Zhang G; Chen Y; Xu J
Sci Adv; 2023 Apr; 9(15):eadc8933. PubMed ID: 37043580
[TBL] [Abstract][Full Text] [Related]
2. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
Front Immunol; 2022; 13():949509. PubMed ID: 36091021
[TBL] [Abstract][Full Text] [Related]
3. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
4. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
5. Identification and Functional Enrichment Analysis of Potential Diagnostic and Therapeutic Targets in Adamantinomatous Craniopharyngioma.
Zou YF; Meng LB; Wang QQ; He ZK; Hu CH; Shan MJ; Wang DY; Yu X
J Comput Biol; 2020 Jan; 27(1):55-68. PubMed ID: 31424286
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma.
Yang J; Hou Z; Wang C; Wang H; Zhang H
Cancer Gene Ther; 2018 Oct; 25(9-10):227-239. PubMed ID: 29681617
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
Apps JR; Martinez-Barbera JP
Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets.
Prince E; Whelan R; Donson A; Staulcup S; Hengartner A; Vijmasi T; Agwu C; Lillehei KO; Foreman NK; Johnston JM; Massimi L; Anderson RCE; Souweidane MM; Naftel RP; Limbrick DD; Grant G; Niazi TN; Dudley R; Kilburn L; Jackson EM; Jallo GI; Ginn K; Smith A; Chern JJ; Lee A; Drapeau A; Krieger MD; Handler MH; Hankinson TC;
Acta Neuropathol Commun; 2020 May; 8(1):68. PubMed ID: 32404202
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
12. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
14. Hub genes for early diagnosis and therapy of adamantinomatous craniopharyngioma.
Zou YF; Zhang SY; Li LW; Jing K; Xia L; Sun CX; Wu B
Medicine (Baltimore); 2022 Sep; 101(37):e30278. PubMed ID: 36123899
[TBL] [Abstract][Full Text] [Related]
15. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
[TBL] [Abstract][Full Text] [Related]
16. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
17. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
18. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
19. Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.
Thimsen V; John N; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Knosp E; Losa M; Buslei R; Hölsken A
Sci Rep; 2017 Nov; 7(1):15856. PubMed ID: 29158570
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
